Novel Treatment Options for Multiple Myeloma

JCO Oncology Practice, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 7, 2025

Multiple myeloma (MM), the second most common hematologic malignancy in United States, is characterized by repeated cycles of remission and relapse, with increasing resistance to treatment after each line therapy. Despite virtually incurable nature MM, recent therapeutic breakthroughs have fundamentally reshaped its landscape. This review explores evolving care paradigms, spanning from newly diagnosed MM relapsed or refractory disease. In frontline setting, strategies shifted beyond their traditional emphasis on autologous stem-cell transplant eligibility a broader categorization patients basis suitability for quadruplet relapsed/refractory novel immunotherapies, including chimeric antigen receptor T-cell (CAR-T) therapies bispecific antibodies, revolutionized treatment, offering new hope previously limited options. Precision medicine playing growing role venetoclax showing significant efficacy t(11;14) translocation, advancing targeted therapy this subgroup. On horizon, investigational CAR-T products cereblon E3 ligase modulators, such as mezigdomide iberdomide, may provide faster, more durable responses compared current therapies. addition, belantamab mafodotin, an antibody-drug conjugate withdrawn US market 2022, verge reapproval positive results randomized trials. While these offer potential, challenges remain managing toxicity, ensuring accessibility, optimizing sequencing strategies. As arsenal expands, need personalized plans that balance quality life becomes even essential.

Language: Английский

Practical guidance on the prevention and management of infection in multiple myeloma patients: A case-based approach

Blood Reviews, Journal Year: 2025, Volume and Issue: unknown, P. 101287 - 101287

Published: April 1, 2025

Language: Английский